MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway

[1]  Zhi Lv,et al.  miR‐134 inhibits osteosarcoma cell invasion and metastasis through targeting MMP1 and MMP3 in vitro and in vivo , 2019, FEBS letters.

[2]  S. Gao,et al.  A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[3]  Li Wang,et al.  Integrative analysis of mRNA and lncRNA profiles identified pathogenetic lncRNAs in esophageal squamous cell carcinoma. , 2018, Gene.

[4]  Anna M. Schmoker,et al.  Fyn‐dependent phosphorylation of PlexinA1 and PlexinA2 at conserved tyrosines is essential for zebrafish eye development , 2018, The FEBS journal.

[5]  W. Cao,et al.  Down-regulation of long non-coding RNA ESCCAL_1 inhibits tumor growth of esophageal squamous cell carcinoma in a xenograft mouse model , 2017, Oncotarget.

[6]  C. Abnet,et al.  Epidemiology of Esophageal Squamous Cell Carcinoma. , 2017, Gastroenterology.

[7]  Lei Liu,et al.  Isoprenaline/β2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis , 2017, BMC Cancer.

[8]  Huanming Yang,et al.  Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. , 2017, European urology.

[9]  Hui Wang,et al.  Prognostic significance of lymph node metastasis in esophageal squamous cell carcinoma. , 2017, Pathology, research and practice.

[10]  Ling Zhang,et al.  FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer. , 2017, Cancer letters.

[11]  Yibo Gao,et al.  High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation , 2017, Journal of Experimental & Clinical Cancer Research.

[12]  Yanhong Sun,et al.  MicroRNA-134 suppresses cell proliferation in gastric cancer cells via targeting of GOLPH3. , 2017, Oncology reports.

[13]  Hui Gao,et al.  MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion. , 2017, Oncology letters.

[14]  Jing He,et al.  miR-134: A Human Cancer Suppressor? , 2016, Molecular therapy. Nucleic acids.

[15]  Lianhong Li,et al.  microRNA -140-5p inhibits colorectal cancer invasion and metastasis by targeting ADAMTS5 and IGFBP5 , 2016, Stem Cell Research & Therapy.

[16]  K. Kawahara,et al.  Plexin A1 signaling confers malignant phenotypes in lung cancer cells. , 2016, Biochemical and biophysical research communications.

[17]  Xiaofang Jiang,et al.  Overexpression of LRIG1 regulates PTEN via MAPK/MEK signaling pathway in esophageal squamous cell carcinoma , 2016, Experimental and therapeutic medicine.

[18]  Baosheng Li,et al.  miR‐134 inhibits non‐small cell lung cancer growth by targeting the epidermal growth factor receptor , 2016, Journal of cellular and molecular medicine.

[19]  M. Sang,et al.  The tumor‐suppressive function of miR‐1 by targeting LASP1 and TAGLN2 in esophageal squamous cell carcinoma , 2016, Journal of gastroenterology and hepatology.

[20]  Shuo Yan,et al.  MicroRNA-29a Promotes Pancreatic Cancer Growth by Inhibiting Tristetraprolin , 2015, Cellular Physiology and Biochemistry.

[21]  J. Li,et al.  miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells. , 2015, DNA and cell biology.

[22]  Xiang-ling Meng,et al.  Decreased Expression of MIR-134 and its Clinical Significance in Human Colorectal Cancer. , 2015, Hepato-gastroenterology.

[23]  P. Duan,et al.  miR-29a activates Hes1 by targeting Nfia in esophageal carcinoma cell line TE-1 , 2014, Oncology letters.

[24]  Xiaodong Zhou,et al.  Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A , 2014, Oncotarget.

[25]  Jianning Zhao,et al.  MiR-143 inhibits EGFR-signaling-dependent osteosarcoma invasion , 2014, Tumor Biology.

[26]  M. Abbaszadegan,et al.  Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development , 2014, Medical Oncology.

[27]  S. Misra,et al.  Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. , 2014, World journal of gastrointestinal oncology.

[28]  W. Guo,et al.  Genome-Wide Screening Identified That miR-134 Acts as a Metastasis Suppressor by Targeting Integrin β1 in Hepatocellular Carcinoma , 2014, PloS one.

[29]  Lirong Zhang,et al.  Implications of Bit1 and AIF overexpressions in esophageal squamous cell carcinoma , 2013, Tumor Biology.

[30]  Yanhong Yu,et al.  miR‐134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non‐small cell lung cancer cells , 2012, FEBS letters.

[31]  C. Croce,et al.  microRNA involvement in human cancer. , 2012, Carcinogenesis.

[32]  Li Zhang,et al.  Clinical characteristics of patients with lung cancer and idiopathic pulmonary fibrosis in China , 2011, Thoracic cancer.

[33]  D. Xie,et al.  Primate‐specific microRNA‐637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling , 2011, Hepatology.

[34]  J. González‐Gallego,et al.  Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: role of the MT1 receptor , 2011, Journal of Pineal Research.

[35]  Xi Chen,et al.  Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. , 2010, Clinical chemistry.

[36]  E. Choi,et al.  Pathological roles of MAPK signaling pathways in human diseases. , 2010, Biochimica et biophysica acta.

[37]  Kangdong Liu,et al.  MAPK/ERK1/2 signaling mediates endothelial-like differentiation of immature DCs in the microenvironment of esophageal squamous cell carcinoma , 2010, Cellular and Molecular Life Sciences.

[38]  H. Friess,et al.  Association of axon guidance factor Semaphorin 3A with poor outcome in pancreatic cancer , 2007, International journal of cancer.